Kraig Biocraft Laboratories In Stock Price, News & Analysis

Kraig Biocraft Laboratories (OTCQB: KBLB) announced a significant production update for its BAM-1 spider silk hybrid strain. The new batch, the largest in the company's history, is ten times the size of the spring trials and showcases record-breaking growth and robustness in silkworms.

The production batch is a major step forward in validating the rearing protocols and demonstrating the scalability of their spider silk production technology. CEO Kim Thompson emphasized that the mission of rapidly commercializing cost-effective and environmentally responsible spider silk production is progressing towards reality. The company plans to release cocooning and processing results over the coming weeks as it targets metric ton production levels.

Kraig Biocraft Laboratories (OTCQB: KBLB) has initiated the production phase for its BAM-1 recombinant spider silk hybrids.

This move follows successful spring production trials, marking the company's largest single batch of spider silk production to date.

The company's CEO, Kim Thompson, emphasized the significance of this milestone, aiming for a metric ton of spider silk production in 2024.

This development is expected to accelerate Kraig Biocraft's 2024 production schedule and cement its position in the commercial spider silk market.

Kraig Biocraft Laboratories (OTCQB: KBLB) announces the production of its BAM-1 recombinant spider silk hybrids, ahead of schedule due to successful production trials. This marks the company’s first true production-scale launch of these hybrids, representing over a 10x increase in production compared to spring trials. The BAM-1 hybrids, created by integrating Dragon Silk™ with robust silkworm strains, have shown excellent hatching yields, strong growth, and no signs of disease. This cycle aims to reach a production milestone of a metric ton of spider silk, with further updates promised in the coming weeks.

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant advancements in the commercialization of its BAM-1 recombinant spider silk production hybrids, first introduced in February 2024. The BAM-1 platform has proven to be the most resilient and efficient system for large-scale spider silk production. This technology has successfully integrated the desirable properties of spider silk into production-ready silkworm strains, resulting in the advanced Dragon SilkTM. CEO Kim Thompson emphasized the scalability and reliability of the BAM-1 hybrids in accelerating the market transition of spider silk technologies. Following successful spring production trials, the company is ahead of its 2024 production schedule and plans to expand production further in the coming weeks.

Kraig Biocraft Laboratories (OTCQB: KBLB) has completed its spring spider silk production trials and is set to expand production in 2024. The company identified five key input parameters—nutrition, climate, genetic, staffing, and rearing conditions—that improved silkworm genetics and production processes, resulting in the largest and strongest silkworms and cocoons to date. Under the guidance of Dr. Nirmal Kumar, the team achieved significant advancements and is now accelerating the launch of larger-scale operations, starting nearly a month ahead of schedule with the next generation of BAM-1 spider silk hybrids.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced significant milestones, particularly the success of its spring production trials for spider silk. The company has heightened its investor communications and reviewed its investor relations (IR) program at the request of OTC Markets Group, ensuring all publications are compliant and factual. A recent editorial by 24/7 Market News highlighted advancements in spider silk, which the company verified as truthful. Kraig Labs has directed Hansel Capital and Karolus Maximus Kapital to provide shareholder updates, emphasizing a commitment to compliance and transparency. The company reported no insider trading or issuance of common stock in the past 90 days, except for the CEO acquiring one restricted share. Kraig Biocraft is focused on scaling production and maintaining high reporting standards.

Kraig Biocraft Laboratories, Inc. announces plans to expand production base into Cambodia to support the growth of its recombinant spider silk production. The Company's successful spring production trials have paved the way for rapid expansion and diversification of operations. With a target of one metric ton production before year's end, the Company aims to capitalize on its recent successes and continue scaling up its operations.

Kraig Biocraft Laboratories (KBLB) has successfully completed its Spring spider silk trials, exceeding expectations and paving the way for commercial scale production of genetically bioengineered spider silk. The trials showcased the strength and resilience of the BAM-1 recombinant spider silk hybrids, with no instances of disease or infection throughout the entire production cycle. Dr. Nirmal Kumar, an expert consultant, oversaw the selective breeding process, optimizing the parental strains for larger cocoons and improved reeling characteristics. The results have positioned Kraig Labs to scale production to metric ton levels.

Kraig Biocraft Laboratories, Inc. (KBLB) announces successful spring production trials of its BAM-1 hybrid parental strains, exceeding expectations for scale, performance, and robustness. The trials demonstrated the readiness for rapid production expansion, marking the most successful cycle in the company's history. The parent strains showed strength and resilience, with no instances of disease. The company is now moving towards scaling production to metric ton levels.